Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation

Kenichiro Doi, Rongshi Li, Shen Shu Sung, Hongwei Wu, Yan Liu, Wanda Manieri, Gowdahalli Krishnegowda, Andy Awwad, Alden Dewey, Xin Liu, Shantu Amin, Chunwei Cheng, Yong Qin, Ernst Schonbrunn, Gary Daughdrill, Thomas P. Loughran, Said Sebti, Hong Gang Wang

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

The anti-apoptotic Bcl-2 family of proteins, including Bcl-2, Bcl-X L and Mcl-1, are well-validated drug targets for cancer treatment. Several small molecules have been designed to interfere with Bcl-2 and its fellow pro-survival family members. While ABT-737 and its orally active analog ABT-263 are the most potent and specific inhibitors to date that bind Bcl-2 and Bcl-X L with high affinity but have a much lower affinity for Mcl-1, they are not very effective as single agents in certain cancer types because of elevated levels of Mcl-1. Accordingly, compounds that specifically target Mcl-1 may overcome this resistance. In this study, we identified and characterized the natural product marinopyrroleAas a novel Mcl-1-specific inhibitor and named it maritoclax. We found that maritoclax binds to Mcl-1, but not Bcl-X L, and is able to disrupt the interaction between Bim and Mcl-1. Moreover, maritoclax induces Mcl-1 degradation via the proteasome system, which is associated with the pro-apoptotic activity of maritoclax. Importantly, maritoclax selectively kills Mcl-1-dependent, but not Bcl-2- or Bcl-X L-dependent, leukemia cells and markedly enhances the efficacy of ABT-737 against hematologic malignancies, including K562, Raji, and multidrugresistant HL60/VCR, by ∼60- to 2000-fold at 1-2 μM. Taken together, these results suggest that maritoclax represents a new class of Mcl-1 inhibitors, which antagonizes Mcl-1 and overcomes ABT-737 resistance by targeting Mcl-1 for degradation.

Original languageEnglish (US)
Pages (from-to)10224-10235
Number of pages12
JournalJournal of Biological Chemistry
Volume287
Issue number13
DOIs
StatePublished - Mar 23 2012

Fingerprint

Degradation
Videocassette recorders
Oncology
Hematologic Neoplasms
Proteasome Endopeptidase Complex
Biological Products
marinopyrrole A
ABT-737
Neoplasms
Leukemia
Molecules
Pharmaceutical Preparations
Proteins

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. / Doi, Kenichiro; Li, Rongshi; Sung, Shen Shu; Wu, Hongwei; Liu, Yan; Manieri, Wanda; Krishnegowda, Gowdahalli; Awwad, Andy; Dewey, Alden; Liu, Xin; Amin, Shantu; Cheng, Chunwei; Qin, Yong; Schonbrunn, Ernst; Daughdrill, Gary; Loughran, Thomas P.; Sebti, Said; Wang, Hong Gang.

In: Journal of Biological Chemistry, Vol. 287, No. 13, 23.03.2012, p. 10224-10235.

Research output: Contribution to journalArticle

Doi, K, Li, R, Sung, SS, Wu, H, Liu, Y, Manieri, W, Krishnegowda, G, Awwad, A, Dewey, A, Liu, X, Amin, S, Cheng, C, Qin, Y, Schonbrunn, E, Daughdrill, G, Loughran, TP, Sebti, S & Wang, HG 2012, 'Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation', Journal of Biological Chemistry, vol. 287, no. 13, pp. 10224-10235. https://doi.org/10.1074/jbc.M111.334532
Doi, Kenichiro ; Li, Rongshi ; Sung, Shen Shu ; Wu, Hongwei ; Liu, Yan ; Manieri, Wanda ; Krishnegowda, Gowdahalli ; Awwad, Andy ; Dewey, Alden ; Liu, Xin ; Amin, Shantu ; Cheng, Chunwei ; Qin, Yong ; Schonbrunn, Ernst ; Daughdrill, Gary ; Loughran, Thomas P. ; Sebti, Said ; Wang, Hong Gang. / Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. In: Journal of Biological Chemistry. 2012 ; Vol. 287, No. 13. pp. 10224-10235.
@article{37207b2be943493ba3b19c35f91b911c,
title = "Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation",
abstract = "The anti-apoptotic Bcl-2 family of proteins, including Bcl-2, Bcl-X L and Mcl-1, are well-validated drug targets for cancer treatment. Several small molecules have been designed to interfere with Bcl-2 and its fellow pro-survival family members. While ABT-737 and its orally active analog ABT-263 are the most potent and specific inhibitors to date that bind Bcl-2 and Bcl-X L with high affinity but have a much lower affinity for Mcl-1, they are not very effective as single agents in certain cancer types because of elevated levels of Mcl-1. Accordingly, compounds that specifically target Mcl-1 may overcome this resistance. In this study, we identified and characterized the natural product marinopyrroleAas a novel Mcl-1-specific inhibitor and named it maritoclax. We found that maritoclax binds to Mcl-1, but not Bcl-X L, and is able to disrupt the interaction between Bim and Mcl-1. Moreover, maritoclax induces Mcl-1 degradation via the proteasome system, which is associated with the pro-apoptotic activity of maritoclax. Importantly, maritoclax selectively kills Mcl-1-dependent, but not Bcl-2- or Bcl-X L-dependent, leukemia cells and markedly enhances the efficacy of ABT-737 against hematologic malignancies, including K562, Raji, and multidrugresistant HL60/VCR, by ∼60- to 2000-fold at 1-2 μM. Taken together, these results suggest that maritoclax represents a new class of Mcl-1 inhibitors, which antagonizes Mcl-1 and overcomes ABT-737 resistance by targeting Mcl-1 for degradation.",
author = "Kenichiro Doi and Rongshi Li and Sung, {Shen Shu} and Hongwei Wu and Yan Liu and Wanda Manieri and Gowdahalli Krishnegowda and Andy Awwad and Alden Dewey and Xin Liu and Shantu Amin and Chunwei Cheng and Yong Qin and Ernst Schonbrunn and Gary Daughdrill and Loughran, {Thomas P.} and Said Sebti and Wang, {Hong Gang}",
year = "2012",
month = "3",
day = "23",
doi = "10.1074/jbc.M111.334532",
language = "English (US)",
volume = "287",
pages = "10224--10235",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "13",

}

TY - JOUR

T1 - Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation

AU - Doi, Kenichiro

AU - Li, Rongshi

AU - Sung, Shen Shu

AU - Wu, Hongwei

AU - Liu, Yan

AU - Manieri, Wanda

AU - Krishnegowda, Gowdahalli

AU - Awwad, Andy

AU - Dewey, Alden

AU - Liu, Xin

AU - Amin, Shantu

AU - Cheng, Chunwei

AU - Qin, Yong

AU - Schonbrunn, Ernst

AU - Daughdrill, Gary

AU - Loughran, Thomas P.

AU - Sebti, Said

AU - Wang, Hong Gang

PY - 2012/3/23

Y1 - 2012/3/23

N2 - The anti-apoptotic Bcl-2 family of proteins, including Bcl-2, Bcl-X L and Mcl-1, are well-validated drug targets for cancer treatment. Several small molecules have been designed to interfere with Bcl-2 and its fellow pro-survival family members. While ABT-737 and its orally active analog ABT-263 are the most potent and specific inhibitors to date that bind Bcl-2 and Bcl-X L with high affinity but have a much lower affinity for Mcl-1, they are not very effective as single agents in certain cancer types because of elevated levels of Mcl-1. Accordingly, compounds that specifically target Mcl-1 may overcome this resistance. In this study, we identified and characterized the natural product marinopyrroleAas a novel Mcl-1-specific inhibitor and named it maritoclax. We found that maritoclax binds to Mcl-1, but not Bcl-X L, and is able to disrupt the interaction between Bim and Mcl-1. Moreover, maritoclax induces Mcl-1 degradation via the proteasome system, which is associated with the pro-apoptotic activity of maritoclax. Importantly, maritoclax selectively kills Mcl-1-dependent, but not Bcl-2- or Bcl-X L-dependent, leukemia cells and markedly enhances the efficacy of ABT-737 against hematologic malignancies, including K562, Raji, and multidrugresistant HL60/VCR, by ∼60- to 2000-fold at 1-2 μM. Taken together, these results suggest that maritoclax represents a new class of Mcl-1 inhibitors, which antagonizes Mcl-1 and overcomes ABT-737 resistance by targeting Mcl-1 for degradation.

AB - The anti-apoptotic Bcl-2 family of proteins, including Bcl-2, Bcl-X L and Mcl-1, are well-validated drug targets for cancer treatment. Several small molecules have been designed to interfere with Bcl-2 and its fellow pro-survival family members. While ABT-737 and its orally active analog ABT-263 are the most potent and specific inhibitors to date that bind Bcl-2 and Bcl-X L with high affinity but have a much lower affinity for Mcl-1, they are not very effective as single agents in certain cancer types because of elevated levels of Mcl-1. Accordingly, compounds that specifically target Mcl-1 may overcome this resistance. In this study, we identified and characterized the natural product marinopyrroleAas a novel Mcl-1-specific inhibitor and named it maritoclax. We found that maritoclax binds to Mcl-1, but not Bcl-X L, and is able to disrupt the interaction between Bim and Mcl-1. Moreover, maritoclax induces Mcl-1 degradation via the proteasome system, which is associated with the pro-apoptotic activity of maritoclax. Importantly, maritoclax selectively kills Mcl-1-dependent, but not Bcl-2- or Bcl-X L-dependent, leukemia cells and markedly enhances the efficacy of ABT-737 against hematologic malignancies, including K562, Raji, and multidrugresistant HL60/VCR, by ∼60- to 2000-fold at 1-2 μM. Taken together, these results suggest that maritoclax represents a new class of Mcl-1 inhibitors, which antagonizes Mcl-1 and overcomes ABT-737 resistance by targeting Mcl-1 for degradation.

UR - http://www.scopus.com/inward/record.url?scp=84858957737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858957737&partnerID=8YFLogxK

U2 - 10.1074/jbc.M111.334532

DO - 10.1074/jbc.M111.334532

M3 - Article

VL - 287

SP - 10224

EP - 10235

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 13

ER -